Evidence map›Paper›PMID 36150544›Full record

ReviewExperimental eye research2022

Does senescence play a role in age-related macular degeneration?

Goldis Malek, Judith Campisi, Koji Kitazawa, Corey Webster, Aparna Lakkaraju, Dorota Skowronska-Krawczyk

Open access · greenAbstract readReview
In one paragraph

Review in Experimental eye research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. A mutation inMolecular vision · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Simultaneous GA and CNV/MNV: incidence, characteristics, and treatments.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Goldis MalekDuke Eye Center, Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA; Department of Pathology, Duke University School of Medicine, Durham, NC, USA. Electronic address: gmalek@duke.edu.
Judith CampisiBuck Institute for Research on Aging, Novato, CA, USA; Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Koji KitazawaBuck Institute for Research on Aging, Novato, CA, USA; Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Corey WebsterBuck Institute for Research on Aging, Novato, CA, USA.
Aparna LakkarajuDepartments of Ophthalmology and Anatomy, School of Medicine, University of California, San Francisco, CA, USA.
Dorota Skowronska-KrawczykDepartment of Physiology and Biophysics, Department of Ophthalmology, Center for Translational Vision Research, School of Medicine, University of California, Irvine, CA, USA.
Buck Institute for Research on Aging · USDuke University · USUniversity of California, Irvine · USUniversity of California, San Francisco · US

Funding

VISION RESEARCHP30EY005722 · NEI · DUKE UNIVERSITY · PI Goldis Malek · 1985 to 2026
$19.3M
Mechanisms of RPE dysfunction in macular degenerations: role of intracellular complement activationR01EY030668 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAKKARAJU, APARNA · 2020 to 2024
$3.5M
Mechanisms of cellular clearance in the retinal pigment epitheliumR01EY023299 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI LAKKARAJU, APARNA · 2015 to 2019
$2.3M
Transfer: Molecular Mechanisms of GlaucomaR01EY027011 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SKOWRONSKA-KRAWCZYK, DOROTA · 2017 to 2022
$2.3M
Nuclear receptor driven mechanisms in aging and AMDR01EY032751 · NEI · DUKE UNIVERSITY · PI MALEK, GOLDIS · 2021 to 2024
$1.8M
Regulation of inflammation and lipid homeostasis by the aryl hydrocarbon receptor in age-related macular degenerationR01EY028160 · NEI · DUKE UNIVERSITY · PI MALEK, GOLDIS · 2018 to 2021
$1.8M
NEI NIH HHS P30 EY005722NEI NIH HHS R01 EY023299NEI NIH HHS R01 EY027011NEI NIH HHS R01 EY028160NEI NIH HHS R01 EY030668NEI NIH HHS R01 EY032751
6 · The paper itself

Abstract

Advanced age is the most established risk factor for developing age-related macular degeneration (AMD), one of the leading causes of visual impairment in the elderly, in Western and developed countries. Similarly, after middle age, there is an exponential increase in pathologic molecular and cellular events that can induce senescence, traditionally defined as an irreversible loss of the cells' ability to divide and most recently reported to also occur in select post-mitotic and terminally differentiated cells, such as neurons. Together these facts raise the question as to whether or not cellular senescence, may play a role in the development of AMD. A number of studies have reported the effect of ocular-relevant inducers of senescence using primarily in vitro models of poorly polarized, actively dividing retinal pigment epithelial (RPE) cell lines. However, in interpretating the data, the fidelity of these culture models to the RPE in vivo, must be considered. Fewer studies have explored the presence and/or impact of senescent cells in in vivo models that present with phenotypic features of AMD, leaving this an open field for further investigation. The goal of this review is to discuss current thoughts on the potential role of senescence in AMD development and progression, with consideration of the model systems used and their relevance to human disease.

Indexed as

Macular DegenerationRetinal Pigment EpitheliumAgedCellular SenescenceHumansMiddle AgedAge-related macular degenerationAgingRetinal pigment epitheliumSenescence

Identifiers

PMID36150544
PMCPMC10032649
OpenAlexW4296629134

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.